Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 11, 2017 09:00 ET | Source: Inovio Pharmaceuticals

Inovio Ebola Vaccine Demonstrates Robust Immune Responses with Favorable Safety Profile in Expanded Clinical Trial

PLYMOUTH MEETING, Pa., April 11, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today preliminary results from the expanded stage of its phase I study, EBOV-001. The...
March 30, 2017 08:00 ET | Source: Inovio Pharmaceuticals

Inovio and Collaborators Receive NIH Grant to Evaluate HIV Immunotherapy PENNVAX®-GP’s Ability to Induce Remission of HIV Infection and End Lifetime of Drug Therapy

PLYMOUTH MEETING, Pa., March 30, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that its academic and industry collaborators received a multi-year $6.95 million...
March 21, 2017 08:00 ET | Source: Inovio Pharmaceuticals

George Bickerstaff Elected to Inovio’s Board of Directors

PLYMOUTH MEETING, Pa., March 21, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today the election of George Bickerstaff to its Board of Directors. Mr....
March 15, 2017 16:05 ET | Source: Inovio Pharmaceuticals

Inovio Pharmaceuticals Reports 2016 Fourth Quarter and Year End Financial Results

PLYMOUTH MEETING, Pa., March 15, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today reported financial results for the fourth quarter and year ended December 31, 2016. Total...
March 09, 2017 08:00 ET | Source: Inovio Pharmaceuticals

Inovio Pharmaceuticals to Report Fourth Quarter and Year End 2016 Financial Results on March 15, 2017

PLYMOUTH MEETING, Pa., March 09, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it will host a conference call and live webcast to discuss its 2016 fourth...
February 27, 2017 07:00 ET | Source: Inovio Pharmaceuticals

Inovio’s SynCon® WT1 Cancer Antigen Breaks Tolerance, Highlights Potential for Universal Cancer Immunotherapy

PLYMOUTH MEETING, Pa., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that its SynCon® WT1 cancer immunotherapy was capable of breaking immune tolerance...
February 23, 2017 07:00 ET | Source: Inovio Pharmaceuticals

Inovio Reports New Positive Clinical Data on Vaccine Advances in the Fight Against Emerging Infectious Diseases

Significant immune responses observed in 100% of Zika-vaccinated subjects and 98% of MERS-vaccinated human subjects in separate phase I studies Data reported at Coalition for Epidemic...
February 13, 2017 06:00 ET | Source: Inovio Pharmaceuticals

Inovio and ApolloBio to Collaborate on Development and Commercialization of HPV Pre-cancer Immunotherapy VGX-3100 in Greater China

PLYMOUTH MEETING, Pa., Feb. 13, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that it has entered into a collaboration and license agreement providing ApolloBio...
January 30, 2017 08:00 ET | Source: Inovio Pharmaceuticals

Inovio Pharmaceuticals to Participate in Upcoming Investment Conferences

PLYMOUTH MEETING, Pa., Jan. 30, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that the Company will participate in the following upcoming investment conferences:...
December 21, 2016 08:00 ET | Source: Inovio Pharmaceuticals

Inovio’s Zika Vaccine Generates Robust Immune Responses in First Human Study

PLYMOUTH MEETING, Pa., Dec. 21, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced its DNA-based Zika vaccine (GLS-5700) generated robust antigen-specific antibody...